MGTX MeiraGTx Holdings plc

Nasdaq meiragtx.com


$ 7.70 $ -0.06 (-0.78 %)    

Wednesday, 19-Nov-2025 13:23:37 EST
QQQ $ 597.08 $ 0.02 (0 %)
DIA $ 461.06 $ -0.43 (-0.09 %)
SPY $ 661.28 $ 0.48 (0.07 %)
TLT $ 89.20 $ -0.02 (-0.02 %)
GLD $ 375.06 $ -2.72 (-0.72 %)
$ 7.75
$ 7.75
$ 7.66 x 41
$ 7.71 x 101
$ 7.43 - $ 7.83
$ 4.55 - $ 9.73
488,499
na
623.8M
$ 1.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-15-2024 12-31-2023 10-K
9 11-14-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-10-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-11-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-14-2019 03-31-2019 10-Q
28 03-26-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-outperform-on-meiragtx-hldgs-raises-price-target-to-16

RBC Capital analyst Lisa Walter maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Outperform and raises the price target from $1...

 chardan-capital-maintains-buy-on-meiragtx-hldgs-maintains-35-price-target

Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.

 meiragtx-hldgs-q3-eps-062-misses-050-estimate-sales-410000k-miss-6960m-estimate

MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0....

 piper-sandler-maintains-overweight-on-meiragtx-hldgs-raises-price-target-to-30

Piper Sandler analyst Allison Bratzel maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Overweight and raises the price target f...

 chardan-capital-maintains-buy-on-meiragtx-hldgs-maintains-35-price-target

Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.

 eli-lilly-expands-genetic-eye-disease-focused-pipeline-with-meiragtx-gene-therapy-collaboration

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children w...

 raymond-james-initiates-coverage-on-meiragtx-hldgs-with-strong-buy-rating-announces-price-target-of-29

Raymond James analyst Christopher Raymond initiates coverage on MeiraGTx Hldgs (NASDAQ:MGTX) with a Strong Buy rating and an...

 chardan-capital-maintains-buy-on-meiragtx-hldgs-maintains-35-price-target

Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.

 meiragtx-hldgs-q2-eps-048-misses-046-estimate-sales-3691m-miss-8003m-estimate

MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0....

 chardan-capital-maintains-buy-on-meiragtx-hldgs-lowers-price-target-to-35

Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and lowers the price target from $...

 meiragtx-hldgs-q1-eps-051-misses-045-estimate-sales-193m-miss-443m-estimate

MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0....

 meiragtx-announces-it-has-been-granted-fda-regenerative-medicine-advanced-therapy-designation-for-aav-gad-for-treatment-of-parkinsons-disease

-  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time ...

 rbc-capital-maintains-outperform-on-meiragtx-hldgs-raises-price-target-to-13

RBC Capital analyst Luca Issi maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Outperform and raises the price target from $11 ...

 meiragtx-collaborates-with-hologen-ai-to-expedite-development-of-parkinsons-candidate-stock-soars

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION